BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim H, Dill S, O'Brien M, Vian L, Li X, Manukyan M, Jain M, Adeojo LW, George J, Perez M, Grom AA, Sutter M, Feldman BM, Yao L, Millwood M, Brundidge A, Pichard DC, Cowen EW, Shi Y, Lu S, Tsai WL, Gadina M, Rider LG, Colbert RA. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis 2020:annrheumdis-2020-218690. [PMID: 32843325 DOI: 10.1136/annrheumdis-2020-218690] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang Z, Zheng Q, Xuan W, Xu X, Lu M, Wu J, Zou L, Xu Y, Xu X. Short-term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis. Front Pediatr 2022;10:962585. [DOI: 10.3389/fped.2022.962585] [Reference Citation Analysis]
2 Tanboon J, Nishino I. Update on dermatomyositis. Curr Opin Neurol 2022. [PMID: 35942671 DOI: 10.1097/WCO.0000000000001091] [Reference Citation Analysis]
3 Hinze C, Dressler F, Schara-schmidt U, Haas J. Juvenile Dermatomyositis. Aktuelle Rheumatologie 2022;47:99-109. [DOI: 10.1055/a-1769-4299] [Reference Citation Analysis]
4 Zhang J, Qi F, Dong J, Tan Y, Gao L, Liu F. Application of Baricitinib in Dermatology. JIR 2022;Volume 15:1935-41. [DOI: 10.2147/jir.s356316] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chuprin J, McCormack L, Richmond JM, Rashighi M. Evaluating the use of JAK inhibitors in inflammatory connective tissue diseases in pediatric patients: an update. Expert Rev Clin Immunol 2022. [PMID: 35209781 DOI: 10.1080/1744666X.2022.2047022] [Reference Citation Analysis]
6 Sun L, Ouyang J, Zeng Z, Zeng C, Ma Y, Zeng F, Wu S. Targeted and activatable nanosystem for fluorescent and optoacoustic imaging of immune-mediated inflammatory diseases and therapy via inhibiting NF-κB/NLRP3 pathways. Bioact Mater 2022;10:79-92. [PMID: 34901531 DOI: 10.1016/j.bioactmat.2021.08.010] [Reference Citation Analysis]
7 Chan Ng PLP, Mopur A, Goh DYT, Ramamurthy MB, Lim MTC, Lim LK, Ooi PL, Ang EY. Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease. Int J Rheum Dis 2021. [PMID: 34882988 DOI: 10.1111/1756-185X.14258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Stenzel W, Goebel HH, Bader-Meunier B, Gitiaux C. Inflammatory myopathies in childhood. Neuromuscul Disord 2021;31:1051-61. [PMID: 34736626 DOI: 10.1016/j.nmd.2021.08.007] [Reference Citation Analysis]
9 Luo Y, Alexander M, Gadina M, O'Shea JJ, Meylan F, Schwartz DM. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. J Allergy Clin Immunol 2021;148:911-25. [PMID: 34625141 DOI: 10.1016/j.jaci.2021.08.004] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
10 Braegelmann C, Niebel D, Ferring-Schmitt S, Fetter T, Landsberg J, Hölzel M, Effern M, Glodde N, Steinbuch S, Bieber T, Wenzel J. Epigallocatechin-3-gallate exhibits anti-inflammatory effects in a human interface dermatitis model-implications for therapy. J Eur Acad Dermatol Venereol 2021. [PMID: 34585800 DOI: 10.1111/jdv.17710] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
11 Ll Wilkinson MG, Deakin CT, Papadopoulou C, Eleftheriou D, Wedderburn LR. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatr Rheumatol Online J 2021;19:146. [PMID: 34563217 DOI: 10.1186/s12969-021-00637-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Orandi AB, Fotis L, Lai J, Morris H, White AJ, French AR, Baszis KW. Favorable outcomes with reduced steroid use in juvenile dermatomyositis. Pediatr Rheumatol Online J 2021;19:127. [PMID: 34404425 DOI: 10.1186/s12969-021-00615-0] [Reference Citation Analysis]
13 Casal-dominguez M, Pinal-fernandez I, Mammen AL. Inhibiting Interferon Pathways in Dermatomyositis: Rationale and Preliminary Evidence. Curr Treat Options in Rheum 2021;7:258-71. [DOI: 10.1007/s40674-021-00182-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mann H, Vencovský J. Clinical Trials in Myositis: Where Do We Stand? Curr Treat Options in Rheum 2021;7:222-42. [DOI: 10.1007/s40674-021-00180-3] [Reference Citation Analysis]